Next Wednesday, the first estimate of Q1 GDP data is due in the US. Analysts at Wells Fargo forecast a reading (q/q annualized) of -1.2%, below market consensus.
Key Quotes:
“The U.S. economy came to a grinding halt in March as workers were sent home and asked to stay there as the nation battled COVID-19. Prior to the domestic outbreak, economic activity was fairly strong at the start of the year. But the suspension of activity in March was so abrupt and far-reaching that we think it was enough to pull first quarter growth negative. There is no corner of the economy that is sheltered from this public health crisis.”
“Personal consumption expenditures will likely be modestly negative in Q1 as consumers began to withdraw themselves from the economy. Business investment spending will be weak, as businesses likely grew cautious and began to pare back spending even before lockdowns were officially put in place. Residential investment may be one of the only sources of strength in Q1, but any momentum likely dried up by quarter-end. In many ways market participants are already looking ahead as the bulk of the COVID-19 hit is expected in Q2.”
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks

EUR/USD climbs to daily highs, targets 1.1200
EUR/USD extended its intraday rebound to the 1.1180 zone, or daily highs, on Tuesday, as the US Dollar remains on the back foot while investors keep digesting the softer-than-expected April inflation data and the recent US-China trade deal.

GBP/USD picks up pace and retests 1.3300
GBP/USD resumes its uptyrend on Tuesday and reclaims the 1.3300 barrier and beyond, propped up by broad-based weakness in the US Dollar. The Dollar’s decline accelerated after lower-than-estimated US inflation readings in April, reinforcing expectations of a patient Federal Reserve.

Gold sticks to daily gains around $3,250
Gold prices pared some of their early-week losses and hovered near $3,250 on Tuesday afternoon, supported by a cautious market tone and softer-than-expected US April CPI data, which helped XAU/USD stabilise.

UnitedHealth stock craters as CEO resigns, insurer suspends guidance Premium
UnitedHealth Group stock slumped 10.4% in Tuesday's premarket after the United States' largest private health insurer said it would suspend guidance for 2025 due to increasing healthcare costs. The sell-off sent shares down to a more than four-year low near $340.

US-China trade truce only emphasizes timeless investing truths
Markets roared back to life as the US and China hit pause on their escalating trade war, with both sides emphasizing mutual respect and dignity. But it wasn’t the fine print that moved markets—it was the mood shift. Investors rushed back into risk assets, betting that the worst might be behind us.